Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00036790 · ClinicalTrials.gov registry record · Phase 1
Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer
A Phase 1 study, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00036790 is a Phase 1 study that has completed, run by University of Wisconsin, Madison.
The verdict
NCT00036790, a Phase 1 study, has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Motexafin gadolinium may increase the effectiveness of doxorubicin by making tumor cells more sensitive to the drug. PURPOSE: Phase I trial to study the effectiveness of combining motexafin gadolinium with doxorubicin in treating patients who have recurrent or metastatic cancer.
Interventions
- DRUG doxorubicin hydrochloride
- DRUG motexafin gadolinium
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00036790
The ClinicalTrials.gov registry entry for NCT00036790 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which doxorubicin hydrochloride is the first listed.
NCT00036790 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00036790 about?
NCT00036790 is a clinical study titled "Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Motexafin gadolinium may increase the effectiveness of doxorubicin by making tumor cells more sensitive to the drug. PURPOSE: Phase I trial to study the effectiveness of combining...
What is the current status of trial NCT00036790?
This trial is currently completed. It is a Phase 1 study. The study started on 2002-02.
What interventions are being tested in trial NCT00036790?
The interventions under investigation include: doxorubicin hydrochloride (DRUG), motexafin gadolinium (DRUG).
Who is sponsoring clinical trial NCT00036790?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.